A spokesman for Valneva said the firm was “exploring options for its Almeida manufacturing facility in Livingston, initially built to produce its Covid-19 vaccine, including a possible sale or a repurposing to produce its vaccine for Japanese Encephalitis, and its chikungunya vaccine, if approved”.
More Stories
Kerr’s skill ‘made the boys cry’
Tufnell predicts Australia win on final day of Ashes
No hope of survivors from MRH-90 helicopter crash in Australia